Eagerly awaiting the launch of Troriluzole, which in December 2024, Biohaven submitted a New Drug Application (NDA) to the FDA for troriluzole, targeting spinocerebellar ataxia (SCA). SCA is a rare neurodegenerative disorder characterized by progressive problems with movement. If approved, troriluzole could become the first FDA-approved treatment for this condition, offering hope to those affected.